Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.

We evaluated the occurrence of acute nonlymphocytic leukemia (ANL) among 1399 women with ovarian cancer who were treated in five randomized clinical trials. Of the 1399 women, 998 had been treated with alkylating agents, and among these, 12 cases of ANL were observed; the expected number was 0.11. Ten patients with ANL had received melphalan, and two chlorambucil. ANL was not observed in 401 women who had been treated with surgery or radiation or both, without alkylating agents. The excess risk of ANL that was associated with alkylating-agent therapy was 5.8 cases per 1000 women per year, and the cumulative seven-year risk of ANL among patients who were treated with chemotherapy alone was indistinguishable from that observed in patients receiving both radiation and chemotherapy. A positive correlation between initial drug dose and the risk of ANL was suggested. These data underscore the need to assess other cytotoxic agents and regimens of drug administration to identify those that do not have harmful late effects.

[1]  J. Goldberg,et al.  Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. , 1981, The New England journal of medicine.

[2]  L. Lagasse,et al.  The role of adjuvant therapy in Stage I ovarian cancer. , 1980, American journal of obstetrics and gynecology.

[3]  L. Lagasse,et al.  Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5‐fluorouracil and dactinomycin or with the combination of cytoxan, 5‐fluorouracil and dactinomycin , 1980, Cancer.

[4]  A. Santoro,et al.  Second malignancies in Hodgkin's disease: a complication of certain forms of treatment. , 1980, British medical journal.

[5]  N. Nissen,et al.  Acute non‐lymphocytic leukemia in patients with ovarian carcinoma following long‐term treatment with treosulfan (=dihydroxybusulfan) , 1980, Cancer.

[6]  H. J. Eyre.  CHEMOTHERAPY OF OVARIAN CARCINOMA , 1979, Clinical obstetrics and gynecology.

[7]  A. Miller,et al.  The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. , 1979, The New England journal of medicine.

[8]  S. Rosenberg,et al.  Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. , 1979, The New England journal of medicine.

[9]  A. Morley,et al.  Residual marrow injury following cytotoxic drugs. , 1979, Leukemia research.

[10]  R. Fisher,et al.  Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. , 1978, The New England journal of medicine.

[11]  R. Hoover,et al.  Second primary neoplasms following ovarian cancer. , 1978, Journal of the National Cancer Institute.

[12]  R. Hoover,et al.  Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism. , 1978, Journal of the National Cancer Institute.

[13]  N. Einhorn†.  Acute leukemia after chemotherapy (melphalan) , 1978, Cancer.

[14]  D G Thomas,et al.  Trend and homogeneity analyses of proportions and life table data. , 1977, Computers and biomedical research, an international journal.

[15]  R. Hoover,et al.  Acute leukemia after alkylating-agent therapy of ovarian cancer. , 1977, The New England journal of medicine.

[16]  J. Trujillo,et al.  Acute leukemia in multiple myeloma. , 1977, Annals of Internal Medicine.

[17]  R. Adamson,et al.  Toxicity of antineoplastic agents in man, chromosomal aberrations antifertility effects, congenital malformations, and carcinogenic potential. , 1975, Advances in cancer research.

[18]  R. Monson,et al.  Analysis of relative survival and proportional mortality. , 1974, Computers and biomedical research, an international journal.

[19]  E. Weisburger.  Carcinogenicity of alkylating agents. , 1966, Public health reports.